首页 | 本学科首页   官方微博 | 高级检索  
     


Endoscopic Retrograde Cholangiopancreatography in Patients with Previous Acute Coronary Syndrome
Authors:Han-Ra Koh  Chang-Hwan Park  Min-Woo Chung  Seon-Young Park  Young-Joon Hong  Myung-Ho Jeong  Hyun-Soo Kim  Sung-Kyu Choi  Jong-Sun Rew
Affiliation:Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
Abstract:

Background/Aims

Endoscopic retrograde cholangiopancreatography (ERCP) is considered a high-risk procedure in patients with previous acute coronary syndrome (ACS); however, clinical studies are rare in the literature. The aim of this study was to investigate the safety and efficacy of ERCP in patients with previous ACS.

Methods

We retrospectively reviewed the medical records of patients with previous ACS who underwent ERCP between January 2007 and August 2012. The clinical characteristics, ERCP diagnoses, treatment results, and complications were analyzed.

Results

Fifty patients underwent ERCP an average of 41.6 months after ACS. The most common indication for ERCP was calculous cholangitis. After deep biliary cannulation, endoscopic sphincterotomy, biliary stone removal and endoscopic biliary drainage were successfully performed. Immediate postsphincterotomy bleeding occurred in seven patients, which was successfully controlled using endoscopic therapy. Elevation of cardiac troponin I levels were observed in three patients (6%) before ERCP, and all of these patients were diagnosed with pancreatobiliary disease combined with recurrent ACS, which was treated with coronary artery stent insertion (n=2) and balloon angioplasty (n=1).

Conclusions

Therapeutic ERCP is effective and safe in patients with previous ACS. Cardiac troponin I elevation should be considered a warning sign for recurrent ACS in patients who undergo ERCP.
Keywords:Cholangiopancreatography   endoscopic retrograde   Acute coronary syndrome   Troponin I
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号